ABSTRACT -The primary antibody deficiency syndromes are a rare group of immunodeficiencies where diagnostic delay remains common due to limited awareness of the existence and heterogeneity of their presenting features. Referral for specialist assessment leads to earlier diagnosis and appropriate therapy to prevent or limit structural organ and tissue damage. Greater education of healthcare professionals is required to ensure prompt recognition and referral to specialists with expertise in the care of primary immunodeficiencies, especially since study of these rare conditions is a minor part of undergraduate and general postgraduate training. Greater awareness would lead to reduced morbidity, improved quality of life and survival outcomes in this patient group.
Purpose
The main objective of this guideline is to inform clinicians about the varied and frequently complex presentations of primary antibody deficiency syndromes and to emphasise the importance of early recognition, diagnosis and referral for appropriate treatment. Specifically, the guideline offers recommendations on the identification of those patients who should be referred to clinical immunology services that are supported by expert specialist immunology laboratory services.
The guideline applies to those patients with the whole spectrum of clinical problems related to primary antibody deficiencies, with the aim of ensuring equity of access to consistently good care and has been developed for the guidance of healthcare professionals who, in their clinical practice, may encounter patients with unsuspected primary antibody deficiencies.
Implications for implementation
These guidelines are intended to impact primarily on education of healthcare professionals and their awareness of primary antibody deficiency. All clinical staff within the hospital setting should consider the possible diagnosis of primary antibody deficiency in a patient presenting with severe, persistent, opportunistic or recurrent infections or with other potential indicator conditions. The latter includes disorders of immune regulation (granulomatous, hypersensitivity or autoimmune disease), a restricted range of malignant diseases (lymphoma, skin or gastric cancer), vaccine failures or, occasionally, stigmata associated with specific deficiency syndromes.
Recognition and referral of patients with suspected primary antibody deficiency is important as appropriate therapy can prevent or reduce infections, and delayed therapy is associated with complications.
Primary antibody deficiency syndromes (Table 1)

Prevalence and clinical presentation
The prevalence of clinically significant primary antibody deficiency is around 1:25,000 to 1:110,000 of the population. Overall, 95% of patients with primary antibody deficiencies present after the age of six years. A relevant history allied to appropriate suspicion and disease awareness, are the most important elements for early recognition and diagnosis of primary antibody deficiency. Patients at any age with recurrent infections (especially in the upper and lower respiratory tracts), those with infections in more than one anatomical site and those in whom the frequency or severity of infection is unusual or out of context should be investigated for possible antibody deficiency (Table 2 ). More rarely, granulomatous, inflammatory or autoimmune features are the initial manifestation of primary antibody deficiency. The European Society for Immunodeficiencies (ESID) has developed an algorithm for clinicians to guide assessment and referral of possible primary immunodeficiencies, including primary antibody deficiencies. 1 The UK Primary Immunodeficiency Network website contains a diagnostic tool developed from this algorithm to help clinicians assess potential primary immunodeficiency disorders (www.ukpin.org.uk). 
Investigations
Good practice points
• A clinical immunologist should initiate treatment with immunoglobulin, after full risk assessment for that patient and provision of written information
• Patients should start therapy in an established immunology centre where specialist immunology nurses can assist with their management
• Specialist immunology nurses should be involved in ongoing management of patients receiving therapy both in the home or hospital setting
• All patients should have the opportunity to be assessed for home therapy if appropriate. Such 'home therapy' programmes are available in specified centres. Guidelines for home immunoglobulin therapy have been approved by the professional medical bodies and by the Department of Health
• Clinical immunologists should continue to review patients regularly on an outpatient basis in order to detect and treat disease progression or onset of complications, assess possible prognostic factors and carry out regular risk assessments for continuing treatment with immunoglobulin or other therapeutic agents
• In patients with structural lung damage, joint management with a respiratory physician should be considered, with the use of prophylactic antibiotics and physiotherapy as required on an individual basis
• Shared care between the clinical immunologist, local organ-based consultant and general practitioner will always be necessary to ensure adequate patient support, prompt treatment of breakthrough infections with appropriate antibiotics and optimal monitoring of remotely delivered immunoglobulin therapy
• Centres delivering care to patients with primary antibody deficiencies should be part of the national governance framework established by the United Kingdom Primary Immunodeficiency Network -a multi-professional grouping of healthcare professionals involved in the delivery of care to patients with primary antibody deficiencies (www.ukpin.org.uk)
The guidelines primary antibody deficiency have an immunoglobulin (Ig) G level of 3 g/l or less, with an IgA level of less than 0.1 g/l and in some antibody deficiencies an IgM level of less than 0.25 g/l. 2, 3 Over 90% of patients with the most common types of antibody deficiency, common variable immunodeficiency disorders, have an IgG level of less than 4.5 g/l at diagnosis. 4 
Diagnostic delay
Patients with primary antibody deficiencies present to a wide variety of clinical specialties other than clinical immunology, but the diagnosis of antibody deficiency is established in far fewer patients seen in these departments than in patients seen in immunology clinics. Diagnostic delay is associated with considerable morbidity, particularly recurrent pneumonias, with secondary structural lung damage such as bronchiectasis and associated pulmonary hypertension and, ultimately, pulmonary heart disease. 5 
Therapy
Immunoglobulin therapy increases survival, leads to a reduction in the rate of bacterial infections, days of antibiotic usage, days of fever and hospital admissions and is equally efficacious in this respect when given by either intravenous (iv) or subcutaneous (SC) routes. 2, 4, [6] [7] [8] Inadequate immunoglobulin replacement therapy or delayed diagnosis places the patient at greater risk of local or systemic recurrent infections. Some of the more common infections are listed in Table 3 . The risk of infection AID ϭ activation-induced cytidine deaminase; BLNK ϭ B cell linker; CVID ϭ common variable immunodeficiency disorders; ICOS ϭ inducible co-Stimulatory receptor; IG-CSR ϭ immunoglobulin class switch recombination; TACI ϭ transmembrane activator and calcium-modulator and cyclophilin-ligand interactor; UNG ϭ uracil-N-glycosylase; XLA ϭ X-linked agammaglobulinaemia.
Site of infection Range reported (%)
Respiratory/chest infections including 37-90 pneumonia (excluding 'bronchitis') Recurrent sinus infections 19-98
GI infections 6-38
Cutaneous infections 1-13 CNS/meningitis 2-9
Septic arthritis/osteomyelitis 1-7 Ophthalmic 1.4-10 CNS ϭ central nervous system; GI ϭ gastrointestinal. remains even when appropriate therapy with replacement immunoglobulin is initiated, although this is reduced compared to untreated patients.
Complications
Despite therapy, patients can develop a number of organspecific and systemic complications (Table 4) , not all of which are related to diagnostic delay or inadequate replacement therapy with immunoglobulin. Some of these occur rarely and require specialist knowledge and experience for appropriate diagnosis and management.
Health-related quality of life (QoL) in untreated or inadequately treated primary antibody deficiency is poor in many areas of daily life. Optimal treatment with subcutaneous immunoglobulin dramatically improves QoL to levels comparable with normal control groups. 9 
Individual needs
In addition to medical needs, patients often require support with issues surrounding employment, travel and other insurance, access to appropriate benefits and support for carers and families. The Primary Immunodeficiency Association provides a vital function in these areas within the UK, and all patients should be provided with information about this organisation. 
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